Last updated: February 20, 2026
What Is the Drug?
NDC 00006-3069 refers to Emgality (galcanezumab-gnlm), a monoclonal antibody developed by Eli Lilly for the treatment of migraine and cluster headaches. It was approved by the FDA in September 2018 for adults with migraine and later for episodic cluster headaches in August 2020.
Market Scope and Size
Market Segments
Patient Population
-
Migraine:
- U.S.: Approximately 39 million individuals affected
- Global: Estimated 1 billion people suffer from migraines, with 20-30% qualifying for preventive therapy
-
Cluster Headache:
- U.S.: Estimated 300,000 individuals
- No precise global figures available due to underdiagnosis
Competitive Landscape
Key Competitors
| Drug |
Class |
Approved Indication |
Market Share (2022) |
Price (per dose) |
Dosing Schedule |
| Emgality (galcanezumab) |
Monoclonal antibody |
Migraine, cluster headaches |
~55% |
$745 |
Monthly or quarterly injections |
| Aimovig (erenumab) |
Monoclonal antibody |
Migraine |
~30% |
$575 |
Monthly injections |
| Ajovy (fremanezumab) |
Monoclonal antibody |
Migraine |
~10% |
$575 |
Monthly or quarterly injections |
| Fremanezumab (Ajovy) |
Same as above |
Migraine |
|
|
|
Market Penetration
- Emgality holds a leading position in the monoclonal antibody class for migraine preventive therapies, with over half of the market share as of 2022.
- Expressed competition is intensifying with newly approved drugs and biosimilars expected to enter the market by 2025.
Pricing Structure
- Average retail price per dose: $745 (assumed for Emgality at 120 mg/monthly dose)
- Annual treatment cost: Approximately $8,940 per patient
- Rebate and insurer negotiation: Lower net prices estimated at $600–$700 per dose depending on insurance and pharmacy benefit management contracts
Revenue Projections (2023-2027)
| Year |
Estimated Patients (Migraine, U.S.) |
Market Penetration |
Revenue Estimate (millions USD) |
| 2023 |
10 million |
25% |
$1,500 |
| 2024 |
12 million |
30% |
$2,160 |
| 2025 |
14 million |
40% |
$3,360 |
| 2026 |
15 million |
45% |
$3,830 |
| 2027 |
16 million |
50% |
$4,400 |
Assumptions:
- Steady increase in diagnosed cases and preventive therapy adoption
- Market share expansion with new indications and competitors' pipeline delays
Regulatory and Patent Outlook
- Patent exclusivity expected until approximately 2030–2032 (patent expiry in the U.S. expected around 2032).
- Potential biosimilar entry post-2029 could pressure prices and market share.
Price Sensitivity and Reimbursement Trends
- Insurance coverage favoring monoclonal antibody preventives pushes price negotiations downward.
- Manufacturers' focus on patient access and rebate strategies influences net selling prices.
Key Takeaways
- Emgality’s dominant share in migraine prevention sustains revenue projections above $4 billion annually by 2027.
- The high price per dose and large patient population underpin profitability, but competitive pressures and biosimilar threats could impact margins.
- Market penetration efforts for cluster headache indications are modest but growing.
- Price erosion anticipated post-2029 when biosimilars or generics could enter the market.
- Payer negotiations and reimbursement policies are critical variables influencing net revenue.
FAQs
1. How does Emgality compare pricing-wise with competitors?
Emgality’s per-dose price is approximately $745, higher than Aimovig and Ajovy at ~$575. Reimbursement strategies, rebates, and negotiated discounts significantly affect net pricing.
2. What are the main factors influencing future revenue projections?
Market penetration rate, competitive entry, insurance coverage, patent protection, and the adoption of new indications.
3. How many patients are eligible for Emgality therapy?
In the U.S., approximately 39 million migraine sufferers with frequent episodes; only a subset are prescribed preventive biologics.
4. What are the regulatory risks for Emgality?
Potential patent challenges, biosimilar approvals, and regulatory delays for new indications could alter revenue trajectory.
5. What is the outlook for biosimilar competition?
Biosimilars for galcanezumab are projected to enter the U.S. market around 2029–2030, likely exerting price and market share pressure.
[1] IQVIA. (2022). Global Pharma Market Report.
[2] FDA. (2018). Approval of Emgality.
[3] Eli Lilly. (2022). Emgality product monograph.
